S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Relay Therapeutics Stock Forecast, Price & News

+2.33 (+4.32 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $56.28
50-Day Range
MA: $45.77
52-Week Range
Now: $56.28
Volume1.42 million shs
Average Volume1.14 million shs
Market Capitalization$5.06 billion
P/E RatioN/A
Dividend YieldN/A
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Overall MarketRank

1.46 out of 5 stars

Medical Sector

466th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

61st out of 177 stocks

Analyst Opinion: 1.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:RLAY



Sales & Book Value

Annual SalesN/A



Market Cap$5.06 billion
Next Earnings DateN/A
OptionableNot Optionable
+2.33 (+4.32 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RLAY News and Ratings via Email

Sign-up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Relay Therapeutics (NASDAQ:RLAY) Frequently Asked Questions

Is Relay Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Relay Therapeutics stock.
View analyst ratings for Relay Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Relay Therapeutics?

Wall Street analysts have given Relay Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Relay Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Relay Therapeutics' CEO?

1,428 employees have rated Relay Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Relay Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) released its earnings results on Thursday, November, 12th. The company reported ($3.00) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $2.66.
View Relay Therapeutics' earnings history

What price target have analysts set for RLAY?

6 equities research analysts have issued twelve-month price targets for Relay Therapeutics' shares. Their forecasts range from $36.00 to $66.00. On average, they anticipate Relay Therapeutics' share price to reach $54.20 in the next year. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for Relay Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Relay Therapeutics' key competitors?

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), Quidel (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

Who are Relay Therapeutics' key executives?

Relay Therapeutics' management team includes the following people:
  • Mr. Alexis A. Borisy, Co-Founder & Independent Exec. Chairman (Age 48, Pay $17.5k)
  • Dr. Sanjiv K. Patel, CEO, Pres & Director (Age 46, Pay $938.92k)
  • Dr. Mark Murcko, Co-Founder & Director (Age 60, Pay $235k)
  • Mr. Brian R. Adams J.D., Gen. Counsel & Sec. (Age 46, Pay $454.17k)
  • Dr. Donald A. Bergstrom, Exec. VP and Head of R&D (Age 48, Pay $585.86k)
  • Mr. Thomas Catinazzo, VP of Fin. (Age 44)
  • Mr. Peter Rahmer, Head of Investor Relations
  • Dr. Deborah Palestrant Ph.D., VP of Corp. Devel. & Strategy
  • Mr. Andy Porter, Exec. VP & Chief People Officer
  • Mr. Jim Watters Ph.D., Sr. VP of Biology

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering on Thursday, July 16th 2020. The company issued 14,700,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

When did the company's lock-up period expire?

Relay Therapeutics' lock-up period expired on Tuesday, January 12th. Relay Therapeutics had issued 20,000,000 shares in its initial public offering on July 16th. The total size of the offering was $400,000,000 based on an initial share price of $20.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%).
View institutional ownership trends for Relay Therapeutics

Which institutional investors are buying Relay Therapeutics stock?

RLAY stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Relay Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Relay Therapeutics?

Shares of RLAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $56.28.

How big of a company is Relay Therapeutics?

Relay Therapeutics has a market capitalization of $5.06 billion. Relay Therapeutics employs 132 workers across the globe.

What is Relay Therapeutics' official website?

The official website for Relay Therapeutics is www.relaytx.com.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-370-8837 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.